KRAS and metastatic colorectal cancer: The PRIME study, a randomized phase III clinical trial with 1183 patients, tested panitumumab–FOLFOX4 versus FOLFOX4 alone in untreated wild-type (WT) KRAS metastatic colorectal cancer.